Epidemiology and risk factors for idiopathic intracranial hypertension.
John Chen, Michael Wall
https://pubmed.ncbi.nlm.nih.gov/24296367/Actively Recruiting
Led by Duke University · Updated on 2026-09-15
60
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are evaluating the effect of tirzepatide on people with Idiopathic Intracranial Hypertension IIH, a condition characterized by increased pressure inside the skull. This randomized, double-blind, placebo-controlled Phase IV trial will compare changes in intracranial pressure over 12 months between participants receiving tirzepatide and those receiving a placebo. The study aims to better understand the treatments impact on this condition using detailed statistical methods. Participants are randomly assigned to receive either tirzepatide or a placebo weekly for one year. The dose increases gradually from 2.5 mg in the first month to 15 mg from month seven through twelve. Both groups follow the same dosing schedule. The study includes two treatment arms and uses a quadruple masking approach to maintain objectivity. During the year-long study, participants will have their intracranial pressure measured from enrollment through the end of treatment. Additional assessments include imaging tests to evaluate retinal nerve fiber layer thickness and changes in papilledema and perimetric mean deviation. Researchers will monitor participants for safety and treatment adherence. The total participation duration covers the full 12 months of treatment, with regular evaluations throughout this period.
CONDITIONS
Tirzepatide in Idiopathic Intracranial Hypertension Trial
A
Alexa N Bramall, MD
B
Beth Perry, RN
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Duke University
Lead Sponsor
Eli Lilly and Company
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Tirzepatide (investigational) | Placebo (trial comparator) | Standard medical therapy (external context) |
|---|---|---|---|
| What it is | Investigational GLP‑1/GIP receptor agonist studied in adults with IIH and obesity to reduce intracranial pressure | Placebo comparator for the tirzepatide intervention | Current first‑line medical treatment combining acetazolamide and weight loss strategies |
| Role in the trial | Assigned investigational treatment arm | Assigned placebo control arm | Not part of trial; represents a usual care comparator based on published therapy |
| Primary use | To evaluate impact on intracranial pressure and optic nerve swelling in IIH | Comparator to assess treatment effect of tirzepatide | Standard intervention intended to lower intracranial pressure and preserve vision |
| How it is given or performed | Dose escalations starting at low weekly doses up to 15 mg over several weeks | Matching placebo administered on same schedule as tirzepatide | Oral acetazolamide combined with structured weight loss interventions |
| Evidence status | Efficacy under investigation; outcomes pending trial results | Placebo control; no therapeutic effect expected | Proven to reduce intracranial pressure and improve visual outcomes in IIH |
| Important risks | Safety profile in IIH not yet established | Placebo has no known direct treatment risk beyond procedural trial procedures | Possible side effects include paresthesia, kidney stones, taste changes; weight loss interventions have varying safety profiles |
| Important limitations | Results not yet available; long-term efficacy and safety unknown | Provides control but does not represent therapeutic option | Weight loss may be difficult to sustain; acetazolamide tolerability issues limit high-dose use |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 12 months
Participants receive weekly doses of tirzepatide or placebo following a gradually increasing dose schedule from 2.5 mg to 15 mg over 12 months.
Weekly visits
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
John Chen, Michael Wall
https://pubmed.ncbi.nlm.nih.gov/24296367/Susan P Mollan, Fizzah Ali, Ghaniah Hassan-Smith...
https://pubmed.ncbi.nlm.nih.gov/26888960/Susan P Mollan, Magda Aguiar, Felicity Evison...
https://pubmed.ncbi.nlm.nih.gov/30356129/Latif Miah, Huw Strafford, Beata Fonferko-Shadrach...
https://pubmed.ncbi.nlm.nih.gov/33472926/Arielle Spitze, Peter Lam, Nagham Al-Zubidi...
https://pubmed.ncbi.nlm.nih.gov/25449938/Duke University
Lead Sponsor
Eli Lilly and Company
Collaborating Sponsor